Akebia Ther (AKBA) stock news · rev $236.2M
Akebia Ther (AKBA) is a drug manufacturers - specialty & generic company listed on US.
This AKBA news page leads with what Akebia Ther filed — not a scraped headline mill.
No cached 8-K sentence for AKBA yet. We will not pad this page with generic market recap.
Latest reported AKBA revenue for 2025-12-31 was $236.2M. Net income was -$5.3M. Revenue was up 47.5% from 2024-12-31 to 2025-12-31. AKBA currently screens at market cap $260.1M.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the AKBA stock page; for the tape open the quote page.
AKBA stock news FAQ
What are AKBA's latest revenue and net income?
Latest cached Akebia Ther (AKBA) revenue for Dec 31, 2025 was $236.2M. Net income was -$5.3M. Statements: https://lician.com/financials/akba
How did AKBA revenue change from the prior cached period?
Cached Akebia Ther (AKBA) revenue was up 47.5% from $160.2M (Dec 31, 2024) to $236.2M (Dec 31, 2025). Statements: https://lician.com/financials/akba
What is AKBA's market cap?
Akebia Ther (AKBA) market cap is $260.1M on the latest cached fundamentals snapshot.
What kind of company is AKBA?
Akebia Ther (AKBA) is a drug manufacturers - specialty & generic company listed on US.
Where is AKBA stock news listed?
Cached stock news for Akebia Ther (AKBA) is listed at https://lician.com/news/akba. Filings: https://lician.com/sec/akba
Not investment advice.